GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1α (HIF-1α) pathways

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 12, 2011, Pages

  Burrows, Natalie ^a   Babur, Muhammad ^a   Resch, Julia ^b,c   Ridsdale, Sophie ^a   Mejin, Melissa ^a   Rowling, Emily J ^a   Brabant, Georg ^b,c   Williams, Kaye J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c Experimental and Clinical Endocrinology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; LACTATE DEHYDROGENASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL MIGRATION; CELL SPREADING; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; THYROID CARCINOMA; TREATMENT RESPONSE; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL HYPOXIA; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INDAZOLES; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SULFONAMIDES; THYROID NEOPLASMS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 83155165424     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1426     Document Type: Article

References (26)

1. Fagin JA, Mitsiades N 2008 Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 22:955-969
2. Paes JE, Ringel MD 2008 Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am 37:375-387, viii-ix (Pubitemid 351698084)
3. Burrows N, Resch J, Cowen RL, von Wasielewski R, Hoang-Vu C, West CM, Williams KJ, Brabant G 2010 Expression of hypoxiainducible factor 1α in thyroid carcinomas. Endocr Relat Cancer 17:61-72
4. Semenza GL 2010 Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29:625-634
5. Semenza G 2002 Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 64:993-998 (Pubitemid 35232274)
6. Kasuno K, Takabuchi S, Fukuda K, Kizaka-Kondoh S, Yodoi J, Adachi T, Semenza GL, Hirota K 2004 Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J Biol Chem 279:2550-2558 (Pubitemid 38114240)
7. Raynaud FI, Eccles SA, Patel S, Alix S, Box G, Chuckowree I, Folkes A, Gowan S, De Haven Brandon A, Di Stefano F, Hayes A, Henley AT, Lensun L, Pergl-Wilson G, Robson A, Saghir N, Zhyvoloup A, McDonald E, Sheldrake P, Shuttleworth S, Valenti M, Wan NC, Clarke PA, Workman P 2009 Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther 8:1725-1738
8. Workman P, Clarke PA, Raynaud FI, van Montfort RL 2010 Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 70:2146-2157
9. Loboda A, Jozkowicz A, Dulak J 2010 HIF-1 and HIF-2 transcription factors: similar but not identical. Mol Cells 29:435-442
10. Cowen RL, Williams KJ, Chinje EC, Jaffar M, Sheppard FC, Telfer BA, Wind NS, Stratford IJ 2004 Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Res 64:1396-1402 (Pubitemid 38235608)
11. Liang CC, Park AY, Guan JL 2007 In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2:329-333 (Pubitemid 47040047)
12. Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, Henley A, Di-Stefano F, Ahmad Z, Guillard S, Bjerke LM, Kelland L, Valenti M, Patterson L, Gowan S, de Haven Brandon A, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Patel S, Saghir N, Parker P, Waterfield M, Workman P 2007 Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 67:5840-5850 (Pubitemid 46985018)
13. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA 2010 Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102:1555-1577
14. Burrows N, Babur M, Resch J, Williams KJ, Brabant G 2011 Hypoxia-inducible factor in thyroid carcinoma. J Thyroid Res 2011:762905
15. Karaca Z, Tanriverdi F, Unluhizarci K, Ozturk F, Gokahmetoglu S, Elbuken G, Cakir I, Bayram F, Kelestimur F 2011 VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 164:277-284
16. Itoh A, Iwase K, Jimbo S, Yamamoto H, Yamamoto N, Kokubo M, Senda T, Nakai A, Nagagasaka A, Nagasaka T, Hibi Y, Seko T 2010 Expression of vascular endothelial growth factor and presence of angiovascular cells in tissues from different thyroid disorders. World J Surg 34:242-248
17. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL 1996 Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604-4613 (Pubitemid 26272112)
18. Brown LM, Cowen RL, Debray C, Eustace A, Erler JT, Sheppard FC, Parker CA, Stratford IJ, Williams KJ 2006 Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharmacol 69:411-418 (Pubitemid 43121938)
19. Weng LP, Gimm O, Kum JB, Smith WM, Zhou XP, Wynford-Thomas D, Leone G, Eng C 2001 Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. Hum Mol Genet 10:251-258 (Pubitemid 32123984)
20. Fassnacht M, Kreissl MC, Weismann D, Allolio B 2009 New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther 123:117-141
21. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely Jr PE, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684
22. Qian Y, Zhong X, Flynn DC, Zheng JZ, Qiao M, Wu C, Dedhar S, Shi X, Jiang BH 2005 ILK mediates actin filament rearrangements and cell migration and invasion through PI3K/Akt/Rac1 signaling. Oncogene 24:3154-3165 (Pubitemid 40695084)
23. Sullivan R, Graham CH 2007 Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 26:319-331 (Pubitemid 47101665)
24. Erler JT, Bennewith KL, Nicolau M, Dornhöfer N, Kong C, Le QT, Chi JT, Jeffrey SS, Giaccia AJ 2006 Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440:1222-1226
25. Sion AM, Figg WD 2006 Lysyl oxidase (LOX) and hypoxia-induced metastases. Cancer Biol Ther 5:909-911
26. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive P 2005 Reduced expression of hypoxia-inducible factor-1α in perinecrotic regions of solid tumors. Cancer research 65:7259-7266 (Pubitemid 41161257)